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recent consensus statement from the American Heart
ssociation defined “resistant hypertension” as blood pres-
ure (BP) that remains above goal (140/90 mm Hg), “in
pite of the concurrent use of three antihypertensive agents
f different classes. . .where all agents are prescribed at
ptimal doses” (1). Usually this would involve treatment
ith an angiotensin-converting enzyme inhibitor or angio-
ensin receptor blocker, a calcium-channel blocker, and a
iuretic. The prevalence of resistant hypertension is poorly
efined worldwide, but surveys in the U.S. (2) suggest that
pproximately one-quarter of treated patients remain un-
ontrolled, even when treated by specialists, whom one
ight assume are appropriately up-titrating treatment. Cur-
ently, there are approximately 1 billion people with hyper-
ension worldwide, which suggests that approximately 250
illion will have resistant hypertension according to the
forementioned definition and assumptions. This is likely to
e an underestimate of the true prevalence because recom-
ended treatment targets are lower (130/80 mm Hg) in
atients most at risk (i.e., those with diabetes, chronic
idney disease), and those with established cardiovascular
isease, in whom the definition of resistant hypertension is
ost likely to apply. Whatever the true figure, resistant
ypertension clearly represents a significant burden of dis-
ase and prompts consideration of the underlying mechanisms.
See page 445
The first question is: “who are these people with resistant
ypertension?” The defining feature for most is resistance to
ystolic pressure control (3). In the Framingham study, of
hose treated for hypertension, 90% achieved a diastolic goal
f 90 mm Hg; less than one-half achieved their systolic
ressure goal (4). Similar and remarkably consistent findings
ave been reported from analyses of the major clinical trials
n which diastolic pressure is invariably controlled in the vast
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.t
From the Department of Cardiovascular Sciences, University of Leicester School of
edicine, Leicester, United Kingdom.ajority of patients, but less than one-half achieve their
ystolic pressure goal (5). Isolated systolic hypertension
epresents a particular challenge. Older age is the strongest
redictor of resistant hypertension. Other potent clinical
redictors include the presence of obesity, target organ
amage (e.g., left ventricular hypertrophy and chronic kid-
ey disease), smoking, and diabetes (1). Ironically, this list
lso identifies patients at highest risk of cardiovascular
vents, in whom control of BP would be particularly beneficial.
The aforementioned characteristics of those most likely
o develop resistant hypertension provide important insights
nto its pathogenesis. The dominant impact of aging sug-
ests that age-related aortic stiffening is likely to be the key
actor (6). The potent contribution of renal impairment also
uggests that salt and water retention plays an important
ole, compounded by the reduced capacity of the stiff arterial
ystem to buffer any increase in volume retention.
Arterial stiffening is of paramount importance in the rise
n systolic BP with age, the associated decline in diastolic
ressure, and the resultant widening of pulse pressure seen
ith aging (6–8). This aortic aging process is related to
tructural changes within the media of the vascular wall (9)
Fig. 1). The aorta is designed to smooth the intermittent
ulsatile flow of blood emerging from the left ventricle, into
mooth flow. The stress of the repetitive strain/relaxation
ycle due to the pulsatile nature of the cardiac output is
rimarily borne by the aortic elastin fibers. Over time, and
specially in the presence of hypertension, these elastin
bers become fatigued and fragment, thereby transferring
he pulsatile stress to the less compliant collagen fibers
ithin the arterial wall. This process accelerates from
iddle age, resulting in the development of a less compliant
r stiffer aorta (7–10). This stiffening process is further
ccelerated by: 1) diabetes, through post-translation modi-
cation of vascular wall collagen by the deposition of
dvanced glycation end-products (11,12); and 2) vascular
all calcification (13). Calcification of the aorta and its
elationship to enhanced arterial stiffness has been recog-
ized for many years. It is known that degenerate and
ragmented elastin fibers are rich in calcium binding sites,
nd it is conceivable that the exponential rise in the
eposition of aortic wall calcium from middle age and its
cceleration in the presence of hypertension reflects elastin
amage (14). However, enhanced vascular wall calcification
as also been noted in smokers, people with diabetes, and
hose with chronic kidney disease, suggesting a multifacto-
ial process (15). Importantly, the risk factors for the
evelopment of resistant hypertension are aligned perfectly
ith those responsible for the pathogenesis of aortic stiff-
ning. This is unlikely to be a casual association; it is more
ikely to be a causal relationship. Increased aortic stiffness
esults in profound disturbances to aortic function and the
ulse pressure wave morphology by: 1) increasing the
haracteristic impedance to flow, perhaps in part explaining
he identification of left ventricular hypertrophy as a risk
f
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February 3, 2009:452–4 Aorta and Resistant Hypertensionactor for resistant hypertension; 2) by increasing pulse wave
elocity (PWV) and reducing the time to wave reflection,
hereby increasing the likelihood of central aortic systolic
ressure augmentation; and 3) by increasing central aortic
ystolic pressure and pulse pressure and an associated rise in
he same brachial pressure parameters with aging—changes
hat will further accentuate aortic stiffness. The increase in
ortic stiffness and reduced aortic capacitance will also
ender the patient more volume sensitive, compounded by
he age-related decline in glomerular filtration rate (16).
oreover, increased stiffness in the aortic arch and carotid
rtery will reduce baroreceptor responsiveness (16), facili-
ating the rise in systolic pressure and bedevilling attempts
o reduce it.
Although the aforementioned evidence is comprehensive
nd compelling and strongly implicates aortic stiffness in the
athogenesis of resistant hypertension, it does not provide
he “smoking gun.” To convince the clinical jury beyond
easonable doubt requires at least 2 further sources of
vidence: 1) that aortic stiffness defines the people with
esistant hypertension; and 2) that reversal of aortic stiffness,
f it could be achieved, would convert a patient from
esistant to responsive with regard to BP-lowering treat-
ent. In this issue of the Journal, Protogerou et al. (17)
rovide intriguing evidence to support the first strand of
dditional evidential support for the aortic stiffness hypoth-
sis, that is, that aortic stiffness defines treatment resistance.
hey report a post-hoc analysis of data from the REASON
Preterax in Regression of Arterial Stiffness in a Controlled
ouble-Blind) study, a randomized clinical trial that pro-
pectively evaluated the effects of 12 months of treatment
ith atenolol versus a low-dose combination therapy of
erindopril/indapamide on BP control and arterial hemo-
Figure 1 Factors Influencing the Development of Aortic Stiffnes
AGE  advanced glycation end-product; IGT  impaired glucose tolerance; LDL ynamics in 375 patients (17). Carotid-femoral PWV, a bell characterized surrogate for aortic stiffness, was mea-
ured at baseline. Patients were then stratified into tertiles of
WV, and their response to BP-lowering therapy over the
ext 12 months was related to their baseline PWV. There
as no impact of baseline PWV on the diastolic BP
esponse to treatment at 12 months; however, the baseline
WV predicted the systolic BP response to treatment.
hose with the highest baseline PWV and, thus, aortic
tiffness, had the least effective systolic BP control, even
espite treatment with more add-on therapy. Moreover, the
redictive value of PWV on the systolic BP response was
ndependent of age, sex, mean BP, and cardiovascular risk
actors. These important findings suggest that aortic stiff-
ess is a strong independent predictor of the likelihood of
esistant hypertension and puts the aorta and its age-related
egeneration at the center of the pathogenesis of resistant
ypertension.
These findings also raise important philosophical ques-
ions about the current treatment strategies for hyperten-
ion. The aorta is the forgotten victim of hypertension.
ortic damage due to hypertension is insidious, progressive,
nd unrelenting. It also sets up a vicious cycle in which
ubtle early damage serves to accelerate the rise in systolic
ressure, which, in turn, causes further degeneration of
ortic function. This sets the stage for the mid-life rise in
ystolic pressure, progressing to isolated systolic hyperten-
ion and resistant systolic hypertension. One approach to
reatment would be to develop novel therapeutics designed
o reverse some of the pathological changes in the aorta and
estore responsiveness to BP-lowering treatments. In this
egard, pilot studies with collagen crosslink breakers were
nitially very promising (18), but subsequent results have
een somewhat disappointing, with no major impact on
ading to Resistant Hypertension
nsity lipoprotein.s Le
low-derachial systolic pressure in humans. This does not preclude
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Aorta and Resistant Hypertension February 3, 2009:452–4he possibility that the crosslink breakers may have pro-
uced important reductions in central aortic systolic pres-
ure, which was not studied. This is important because the
rachial BP response to treatment does not always faithfully
eflect the impact of drugs on central aortic pressures (19).
here is, however, a simpler approach. Why not identify
ounger people with mild hypertension and disproportion-
te stiffening of their aortas for their age, and treat them
arly with BP-lowering therapy? The rationale is that
ressure-mediated mechanical stress is the key factor result-
ng in elastin fragmentation and aortic stiffening. Thus,
reating the cause and preventing progression of early aortic
amage should prevent the relentless rise in systolic pressure
nd ultimately, the costly and often ineffective multidrug
reatment of resistant hypertension. Put simply, 1 drug or 4!
obody is born with resistant hypertension, and preventing
ts development by limiting aortic damage is likely to be more
ffective than treating it once aortic damage is established.
eprint requests and correspondence: Dr. Bryan Williams,
rofessor of Medicine, Clinical Sciences Building, Leicester Royal
nfirmary, P.O. Box 65, Leicester, LE2 7LX, United Kingdom.
-mail: bw17@le.ac.uk.
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